Novel insight into the inflammatory and cellular responses following experimental Glaucoma surgery: A roadmap for inhibiting Fibrosis

Current Molecular Medicine

Volumn 13, Issue 6, 2013, Pages 911-928

  Seet, L F ^a,b,c   Finger, S N ^a   Chu, S W L ^a   Toh, L Z ^a   Wong, T T ^a,b,d,e  

^a SINGAPORE EYE RESEARCH INSTITUTE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

^d SINGAPORE NATIONAL EYE CENTRE   (Singapore)

^e NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

Angiogenesis; Fibrosis; Glaucoma; Inflammation; Subconjunctival fibroblasts; Surgery

Indexed keywords

CD3 ANTIGEN; CD31 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; COLLAGEN TYPE 1; CXCL1 CHEMOKINE; CXCL9 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; FIBRONECTIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GELATINASE A; GELATINASE B; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERSTITIAL COLLAGENASE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MATRIX METALLOPROTEINASE 14; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEONECTIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; STROMELYSIN; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROSIS; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GLAUCOMA SURGERY; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLARIZATION MICROSCOPY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WOUND HEALING;

EID: 84880403765     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/15665240113139990021     Document Type: Article

References (60)

1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006; 90: 262-267.
2. Heijl A, Leske MC, Bengtsson B. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol 2002; 120: 1268-1278.
3. Kass MA, Heuer DK, Higginbotham EJ, et al. The ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 701-713.
4. Seet LF, Su R, Barathi VA, et al. SPARC deficiency results in improved surgical survival in a novel mouse model of glaucoma filtration surgery. PLoS One 2010; 5: e9415.
5. Seet LF, Lee WS, Su R, Finger S, Crowston JG, Wong TT. Validation of the glaucoma filtration surgical mouse model for anti-fibrotic drug evaluation. Mol Med 2011; 17: 557-567.
6. Radcliffe NM. Trabeculectomy revision as a treatment for failed trabeculectomy. Glaucoma Today 2010; Fall: 25-28.
7. Greenfield DS, Suner IJ. Miller MP. Endophthalmitis after filtering surgery with mitomycin. Arch Ophthalmol 1996; 114: 943-949.
8. Higginbotham EJ, Stevens RK, Musch DC. Bleb-related endophthalmitis after trabeculectomy with mitomycin C. Ophthalmol 1996; 103: 650-656.
9. Saika S, Yamanaka O, Baba Y, et al. Accumulation of latent transforming growth factor-beta binding protein-1 and TGF beta 1 in extracellular matrix of filtering bleb and of cultured human subconjunctival fibroblasts. Graefes Arch Clin Exp Ophthalmol 2001; 239: 234-241.
10. Broadway DC, Bates AK, Lightman SL, Grierson I, Hitchings RA. The importance of cellular changes in the conjunctiva of patients with uveitic glaucoma undergoing trabeculectomy. Eye 1993; 7: 495-501.
11. Yaldo MK, Stamper RL. Long-term effects of mitomycin on filtering blebs. Lack of fibrovascular proliferative response following severe inflammation. Arch Ophthalmol 1993; 111: 824-826.
12. Chang L, Crowston JG, Sabin CA, Khaw PT, Akbar AN. Human tenon's fibroblast-produced IFNJ3 and the prevention of T-cell apoptosis. Invest Ophthalmol Vis Sci 2001; 42: 1531-1538.
13. Hitchings RA, Grierson I. Clinico pathological correlation in eyes with failed fistulizing surgery. Trans Ophthalmol Soc UK 1983; 103: 84-88.
14. Mosser D. The many faces of macrophages. J Leukoc Biol 2003; 73: 209-212.
15. Andersen CL, Jensen JL, Orntoft TF. Normalization of realtime quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 2004; 64: 5245-5250.
16. Brekken RA, Puolakkainen P, Graves DC, Workman G, Lubkin SR, Sage EH. Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM. J Clin Invest 2003; 111: 487-495.
17. Bradshaw AD, Puolakkainen P, Dasgupta J, Davidson JM, Wght TN, Sage EH. SPARC-null mice display abnormalities in the dermis characterized by decreased collagen fibril diameter and reduced tensile strength. J Invest Derm 2003; 120: 949-955.
18. Sullivan MM, Barker TH, Funk SE, et al. Matricellular Hevin regulates decorin production and collagen assembly. J Biol Chem 2006; 281: 27621-27632.
19. Seet LF, Su R, Toh LZ, Wong, TT. In vitro analyses of the anti-fibrotic effect of SPARC silencing in human Tenon's fibroblasts: comparisons with mitomycin-C. J Cell Mol Med 2012; 16: 1245-1259.
20. Cordeiro MF. Role of transforming rowth factor beta in conjunctival scarring. Clin Sci 2003; 104: 181-187.
21. Cordeiro MF, Bhattacharya SS, Schultz GS, Khaw PT. TGFbeta1,-beta2, and -beta3 in vitro: biphasic effects on Tenon's fibroblast contraction, proliferation, and migration. Invest Ophthalmol Vis Sci 2000; 41: 756-763.
22. Deryugina EI, Ratnikov B, Monosov E, et al. MT1-MMP initiates activation of pro-MMP-2 and integrin alphavbeta3 promotes maturation of MMP-2 in breast carcinoma cells. Exp Cell Res 2001; 263: 209-223.
23. Engelhardt E, Toksoy A, Goebeler M, Debus S, Bröcker EB, Gillitzer R. Chemokines IL-8, GROalpha, MCP-1, IP-10, and Mig are sequentially and differentially expressed during phase-specific infiltration of leukocyte subsets in human wound healing. Am J Pathol 1998; 153: 1849-1860.
24. Strieter RM, Kunkel SL, Arenberg DA, Burdick MD, Polverini PJ. Interferon gamma-inducible protein 10 (IP-10), a member of the C-X-C chemokine family, is an inhibitor of angiogenesis. Biochem Biophys Res Commun 1995; 210: 51-57.
25. Belperio JA, Keane MP, Arenberg DA, et al. CXC chemokines in angiogenesis. J Leukoc Biol 2000; 68: 1-8.
26. nd. Wound healing in glaucoma filtering surgery. Surv Ophthalmol 1987; 32: 149-170.
27. Jampel HD, McGuigan LJ, Dunkelberger GR, L'Hernault NL, Quigley HA. Cellular proliferation after experimental glaucoma filtration surgery. Arch Ophthalmol 1988; 106: 89-94.
28. Leask A, Abraham DJ. TGF-p signaling and the fibrotic response. FASEB J 2004; 18: 816-27.
29. Webster NL, Crowe SM. Matrix metalloproteinases, their production by monocytes and macrophages and their potential role in HIV-related diseases. J Leukoc Biol 2006; 80: 1052-66.
30. Kumar V, Abbas AK, Fausto N. Tissue renewal and repair: regeneration, healing and fibrosis. In Pathologic Basis of Disease. Philadelphia PA: Elsevier Saunders 2005; 87-118.
31. Hoekstra T, Geleijnse JM, Schouten EG, Kluft C. Plasminogen activator inhibitor-type 1: its plasma determinants and relation with cardiovascular risk. Thromb Haemost 2004; 91: 861-872.
32. Juhan-Vague I, Alessi MC, Mavri A, Morange PE. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 2003; 1: 1575-1579.
33. Vaughan DE. Angiotensin and vascular fibrinolytic balance. Am J Hypertens 2002; 15: 3S-8S.
34. Eddy AA. Serine proteases, inhibitors and receptors in renal fibrosis. Thromb Haemost 2009; 101: 656-664.
35. Eddy AA, Fogo AB. Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action. J Am Soc Nephrol 2006; 17: 2999-3012.
36. Huang Y, Noble NA. PAI-1 as a target in kidney disease. Curr Drug Targets 2007; 8: 1007-1015.
37. Dellas C, Loskutoff DJ. Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost 2005; 93: 631-640.
38. Arndt PG, Young SK, Worthen GS. Regulation of lipopolysaccharide-induced lung inflammation by plasminogen activator inhibitor-1 through a JNK-mediated pathway. J Immunol 2005; 175: 4049-4059.
39. Tonnesen MG, Feng X, Clark RA. Angiogenesis in wound healing. J Invest Dermatol Symp Proc 2000; 5: 40-46.
40. Sawano A, Iwai S, Sakurai Y, et al. Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood 2001; 97: 785-791.
41. Cursiefen C, Chen L, Borges LP, et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest 2004; 113: 1040-1050.
42. Horiuchi T, Weller PF. Expression of vascular endothelial growth factor by human eosinophils: upregulation by granulocyte macrophage colony-stimulating factor and interleukin-5. Am J Respir Cell Mol Biol 1997; 17: 70-77.
43. Chen BD, Clark CR, Chou TH. Granulocyte/macrophage colony-stimulating factor stimulates monocyte and tissue macrophage proliferation and enhances their responsiveness to macrophage colony-stimulating factor. Blood 1988; 71: 997-1002.
44. Bussolino F, Ziche M, Wang JM, et al. In vitro and in vivo activation of endothelial cells by colony-stimulating factors. J Clin Invest 1991; 87: 986-995.
45. Hamilton J. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 2008; 8: 533-544.
46. Shi Y, Liu CH, Roberts AI, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know. Cell Res 2006; 16: 126-133.
47. Coelho AL, Hogaboam CM, Kunkel SL. Chemokines provide the sustained inflammatory bridge between innate and acquired immunity. Cytokine Growth Factor Rev 2005; 16: 553-560.
48. Strieter RM, Belperio JA, Keane MP. CXC chemokines in angiogenesis related to pulmonary fibrosis. Chest 2002; 122: 298S-301S.
49. Bernardini G, Ribatti D, Spinetti G, et al. Analysis of the role of chemokines in angiogenesis. J Immunol Methods 2003; 273: 83-101.
50. Chong RS, Jiang YZ, Boey PY, et al. Tear cytokine profile in medicated glaucoma patients: effect of monocyte chemoattractant protein 1 on early posttrabeculectomy outcome. Ophthalmol 2010; 117: 2353-2358.
51. Yoshimura A, Wakabayashi Y, Mori T. Cellular and molecular basis for the regulation of inflammation by TGF-p. J Biochem 2010; 147: 781-792.
52. Cordeiro MF, Bhattacharya SS, Schultz GS, Khaw PT. TGF-beta1, -beta2, and -beta3 in vitro: biphasic effects on Tenon's fibroblast contraction, proliferation, and migration. Invest Ophthalmol Vis Sci 2000; 41: 756-763.
53. Werner S, Grose R. Regulation of wound healing by growth factors and cytokines. Physiol Rev 2003; 83: 835-870.
54. Grehn F, Hollo G, Khaw P, et al. Factors affecting the outcome of trabeculectomy: An analysis based on combined data from two phase III studies of an antibody to transforming growth factor b2, CAT-152. Ophthalmol 2007; 114: 1831-1838.
55. Khaw P, Grehn F, Hollo G, et al. A phase III study of subconjunctival human anti-transforming growth factor-b2 monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy. Ophthalmol 2007; 114: 1822-1830.
56. Olsson A-K, Dimberg A, Kreuger J, Claesson-Welsh L. Vascular receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 2006; 7: 359-371.
57. Hamilton J. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 2008; 8: 533-544.
58. Proudfoot AE, Power CA, Schwarz MK. Anti-chemokine small molecule drugs: a promising future? Expert Opin Investig Drugs 2010; 19: 345-355.
59. Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 2012; 11: 633-652.
60. Hawinkels LJ, ten Dijke P. Exploring anti-TGF-p therapies in cancer and fibrosis. Growth Factors 2011; 29: 140-152.